Daxor Corporation (NASDAQ:DXR) Stock Short Interest Report for October

Daxor Corporation (NASDAQ:DXR) saw a significant drop in short interest in the month of October. As of October 15th, there was short interest totaling 3,374 shares, a drop of 51.5% from the September 30th total of 6,959 shares. Currently, 0.1% of the shares of the company are short sold. Based on an average daily volume of 12,606 shares, the short-interest ratio is presently 0.3 days.

Daxor Trading Up 3.1%

Shares of Daxor stock traded up $0.28 during trading on Friday, reaching $9.20. The company’s stock had a trading volume of 28,009 shares, compared to its average volume of 11,221. The business’s 50-day moving average price is $10.40 and its 200-day moving average price is $10.76. Daxor has a 52 week low of $8.40 and a 52 week high of $14.76.

Institutional Trading of Daxor

A number of institutional investors have recently bought and sold shares of DXR. Aristides Capital LLC acquired a new position in shares of Daxor during the 1st quarter worth approximately $403,000. Susquehanna International Group LLP increased its holdings in shares of Daxor by 97.7% during the second quarter. Susquehanna International Group LLP now owns 27,131 shares of the company’s stock worth $275,000 after purchasing an additional 13,411 shares during the period. Empirical Financial Services LLC d.b.a. Empirical Wealth Management acquired a new stake in shares of Daxor in the first quarter valued at approximately $245,000. Finally, Crescent Grove Advisors LLC acquired a new stake in shares of Daxor in the first quarter valued at approximately $104,000. Institutional investors own 1.34% of the company’s stock.

Analysts Set New Price Targets

Separately, Weiss Ratings reissued a “hold (c)” rating on shares of Daxor in a report on Monday, September 21st. One investment analyst has rated the stock with a Buy rating and one has assigned a Hold rating to the company. According to MarketBeat.com, Daxor presently has a consensus rating of “Moderate Buy”.

About Daxor

Daxor Corporation (NASDAQ: DXR) is a medical device and biotechnology company focused on blood-volume measurement and related diagnostic applications. Its primary product is the BVA-100 Blood Volume Analyzer, a system designed to measure a patient’s total blood volume, plasma volume, red blood cell volume and hematocrit.

The BVA-100 uses a blood sample and an iodine-131-labeled albumin tracer to provide quantitative blood-volume measurements. The technology is intended to support clinical assessment and management in areas including heart failure, critical care, kidney disease, blood disorders and perioperative care, where accurate information about a patient’s fluid and blood-volume status can assist treatment decisions.

Daxor markets its technology primarily to hospitals and other healthcare providers and also supports clinical research involving blood-volume measurement.